CVM vs. CGTX, TIL, DTIL, ELUT, PLX, ATHA, TSBX, GRTS, ATRA, and ALVR
Should you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Cognition Therapeutics (CGTX), Instil Bio (TIL), Precision BioSciences (DTIL), Elutia (ELUT), Protalix BioTherapeutics (PLX), Athira Pharma (ATHA), Turnstone Biologics (TSBX), Gritstone bio (GRTS), Atara Biotherapeutics (ATRA), and AlloVir (ALVR). These companies are all part of the "biological products, except diagnostic" industry.
Cognition Therapeutics (NASDAQ:CGTX) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.
43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 23.8% of Cognition Therapeutics shares are held by insiders. Comparatively, 16.2% of CEL-SCI shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, CEL-SCI had 4 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for CEL-SCI and 0 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.50 beat CEL-SCI's score of 0.00 indicating that CEL-SCI is being referred to more favorably in the news media.
Cognition Therapeutics received 8 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 53.33% of users gave Cognition Therapeutics an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.
CEL-SCI's return on equity of -98.65% beat Cognition Therapeutics' return on equity.
Cognition Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.
Cognition Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks.
Cognition Therapeutics currently has a consensus target price of $6.67, suggesting a potential upside of 240.14%. Given CEL-SCI's higher probable upside, equities analysts clearly believe Cognition Therapeutics is more favorable than CEL-SCI.
Summary
Cognition Therapeutics beats CEL-SCI on 10 of the 14 factors compared between the two stocks.
Get CEL-SCI News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
